Verteporfin photodynamic therapy for neovascular age-related ...
Verteporfin photodynamic therapy for neovascular age-related ... Verteporfin photodynamic therapy for neovascular age-related ...
90 Appendix 1THE VERTEPORFIN PHOTODYNAMIC THERAPY COHORTSTUDY FOR THE UNITED KINGDOMManual of OperationsVersion 2.123 December 2005Principal Investigators:Professor Usha Chakravarthy, Queen’s University BelfastMr Simon Harding, St Paul’s Eye Unit, LiverpoolDr Barnaby Reeves, London School of Hygiene and Tropical MedicineOn behalf of the Royal College of Ophthalmologists, London
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 691LIST OF ABBREVIATIONSAMDCARFCNVCSDPBDVAETDRSFADGLDGPlogMARLRECLSCGMDVAMRECNEIVFQNICENCCHTAPCTPDTQoLRCOphthSDSF-36SFRADSSRVFTAP studyVIP studyAge-related macular degenerationCentral Angiographic Resource Facility (Belfast)Choroidal neo-vascularisationContrast sensitivityDesignated providerBinocular distance visual acuityEarly Treatment for Diabetic Retinopathy StudyFinal appraisal determinationGreatest lesion diameterGeneral practitionerLog minimum angle of resolutionLocal research ethics committeeLocal specialist commissioning groupMonocular distance visual acuityMulti-centre research ethics committeeNational Eye Institute Visual Functioning QuestionnaireNational Institute for Clinical ExcellenceNational Coordinating Centre for Health Technology AssessmentPrimary care trustPhotodynamic therapyQuality of lifeRoyal College of OphthalmologistsStandard deviationShort-Form 36 item questionnaireSub-Foveal RADiotheraphy StudySelf-reported visual function‘Treatment of Age-related macular degeneration by photodynamicTherapy’ study‘Visudyne In Photodynamic therapy’ study© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
- Page 54 and 55: 40 Results (1) - study cohortTABLE
- Page 56 and 57: 42 Results (1) - study cohortTABLE
- Page 58 and 59: 44 Results (1) - study cohortTABLE
- Page 60 and 61: 46 Results (2) - objectives A, B, C
- Page 62 and 63: 48 Results (2) - objectives A, B, C
- Page 64 and 65: 50 Results (2) - objectives A, B, C
- Page 66 and 67: 52 Results (2) - objectives A, B, C
- Page 69 and 70: DOI: 10.3310/hta16060Health Technol
- Page 71 and 72: DOI: 10.3310/hta16060Health Technol
- Page 73 and 74: DOI: 10.3310/hta16060Health Technol
- Page 75 and 76: DOI: 10.3310/hta16060Health Technol
- Page 77: DOI: 10.3310/hta16060Health Technol
- Page 80 and 81: 66 Discussion of resultsStrengths a
- Page 82 and 83: 68 Discussion of resultsThe VPDT st
- Page 84 and 85: 70 Discussion of resultsOur analyse
- Page 86 and 87: 72 Discussion of resultsA further c
- Page 88 and 89: 74 Discussion of resultsVPDT. It is
- Page 91 and 92: DOI: 10.3310/hta16060Health Technol
- Page 93 and 94: DOI: 10.3310/hta16060Health Technol
- Page 95: DOI: 10.3310/hta16060Health Technol
- Page 98 and 99: 84 References16. Stelmack J. Qualit
- Page 100 and 101: 86 References49. Guymer RH, Chiu AW
- Page 102 and 103: 88 References83. Margrain TH. Minim
- Page 106 and 107: 92 Appendix 11. Overview of Manual
- Page 108 and 109: 94 Appendix 1And, if also collectin
- Page 110 and 111: 96 Appendix 1more patients in the v
- Page 112 and 113: 98 Appendix 12.4 Limitations of the
- Page 114 and 115: 100 Appendix 1Box 2 Key advantages
- Page 116 and 117: 102 Appendix 14. Study population4.
- Page 118 and 119: 104 Appendix 15. Recruitment to the
- Page 120 and 121: 106 Appendix 16. Background data co
- Page 122 and 123: 108 Appendix 1Table 1: Schedule of
- Page 124 and 125: 110 Appendix 1The Verteporfin Photo
- Page 126 and 127: 112 Appendix 1• Additional clinic
- Page 128 and 129: 114 Appendix 18. Recording adverse
- Page 130 and 131: 116 Appendix 1level of benefit from
- Page 132 and 133: 118 Appendix 1• comparison of num
- Page 134 and 135: 120 Appendix 110.6 Sub-group analys
- Page 136 and 137: 122 Appendix 112. Data issues12.1 D
- Page 138 and 139: 124 Appendix 113. Organisation13.1
- Page 140 and 141: 126 Appendix 114. References[1] Ref
- Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
- Page 144 and 145: 130 Appendix 1Appendix 1: Classifyi
- Page 146 and 147: 132 Appendix 1Liverpool re-treatmen
- Page 148 and 149: 134 Appendix 1Service StructurePlea
- Page 150 and 151: 136 Appendix 1Has your photographer
- Page 152 and 153: 138 Appendix 1There are many differ
90 Appendix 1THE VERTEPORFIN PHOTODYNAMIC THERAPY COHORTSTUDY FOR THE UNITED KINGDOMManual of OperationsVersion 2.123 December 2005Principal Investigators:Professor Usha Chakravarthy, Queen’s University BelfastMr Simon Harding, St Paul’s Eye Unit, LiverpoolDr Barnaby Reeves, London School of Hygiene and Tropical MedicineOn behalf of the Royal College of Ophthalmologists, London
Change language